165 related articles for article (PubMed ID: 27388754)
1. Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake.
Cheng Q; Wållberg H; Grafström J; Lu L; Thorell JO; Hägg Olofsson M; Linder S; Johansson K; Tegnebratt T; Arnér ES; Stone-Elander S; Ahlzén HS; Ståhl S;
EJNMMI Res; 2016 Dec; 6(1):58. PubMed ID: 27388754
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z
Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of [
Oroujeni M; Garousi J; Andersson KG; Löfblom J; Mitran B; Orlova A; Tolmachev V
Cells; 2018 Sep; 7(9):. PubMed ID: 30231504
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
6. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
Tolmachev V; Friedman M; Sandström M; Eriksson TL; Rosik D; Hodik M; Ståhl S; Frejd FY; Orlova A
J Nucl Med; 2009 Feb; 50(2):274-83. PubMed ID: 19164241
[TBL] [Abstract][Full Text] [Related]
7. HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
Wållberg H; Grafström J; Cheng Q; Lu L; Martinsson Ahlzén HS; Samén E; Thorell JO; Johansson K; Dunås F; Olofsson MH; Stone-Elander S; Arnér ES; Ståhl S
J Nucl Med; 2012 Sep; 53(9):1446-53. PubMed ID: 22872744
[TBL] [Abstract][Full Text] [Related]
8. Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.
Burley TA; Da Pieve C; Martins CD; Ciobota DM; Allott L; Oyen WJG; Harrington KJ; Smith G; Kramer-Marek G
J Nucl Med; 2019 Mar; 60(3):353-361. PubMed ID: 30213849
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.
Andersson KG; Oroujeni M; Garousi J; Mitran B; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Dec; 49(6):2285-2293. PubMed ID: 27748899
[TBL] [Abstract][Full Text] [Related]
10. PET of EGFR expression with an 18F-labeled affibody molecule.
Miao Z; Ren G; Liu H; Qi S; Wu S; Cheng Z
J Nucl Med; 2012 Jul; 53(7):1110-8. PubMed ID: 22689926
[TBL] [Abstract][Full Text] [Related]
11. The Use of a Non-Conventional Long-Lived Gallium Radioisotope
Oroujeni M; Xu T; Gagnon K; Rinne SS; Weis J; Garousi J; Andersson KG; Löfblom J; Orlova A; Tolmachev V
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33672373
[TBL] [Abstract][Full Text] [Related]
12. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
[TBL] [Abstract][Full Text] [Related]
13. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
14. PET imaging of EGFR expression using an
Cheng S; Jacobson O; Zhu G; Chen Z; Liang SH; Tian R; Yang Z; Niu G; Zhu X; Chen X
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):948-956. PubMed ID: 30069577
[TBL] [Abstract][Full Text] [Related]
15. The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.
Garousi J; Andersson KG; Dam JH; Olsen BB; Mitran B; Orlova A; Buijs J; Ståhl S; Löfblom J; Thisgaard H; Tolmachev V
Sci Rep; 2017 Jul; 7(1):5961. PubMed ID: 28729680
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells.
Nordberg E; Orlova A; Friedman M; Tolmachev V; Ståhl S; Nilsson FY; Glimelius B; Carlsson J
Oncol Rep; 2008 Apr; 19(4):853-7. PubMed ID: 18357367
[TBL] [Abstract][Full Text] [Related]
17. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
18. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
19. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts.
Paquette M; Phoenix S; Lawson C; Guérin B; Lecomte R; Tai LH; Turcotte ÉE; Leyton JV
EJNMMI Res; 2020 Jun; 10(1):69. PubMed ID: 32592121
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]